AstraZeneca Sets New Deadlines for MYSTIC Trial
January 17 2017 - 2:55AM
Dow Jones News
By Olga Cotaga
LONDON--AstraZeneca PLC (AZN.LN) said Tuesday it expects to
report progression-free survival data for the lung cancer
randomized MYSTIC trial in mid-2017, and final overall survival
data from the trial in 2018 at the latest.
While the focus remains on exploring the benefit of durvalumab
and tremelimumab as a combination therapy, the pharmaceutical
company will focus the MYSTIC trial on including overall survival
and progression-free survival data in durvalumab monotherapy, it
said.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
January 17, 2017 02:40 ET (07:40 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024